Skip Navigation

Cardiovascular Research 2003 57(3):775-783; doi:10.1016/S0008-6363(02)00789-7
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Der Sarkissian, S.
Right arrow Articles by deBlois, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Der Sarkissian, S.
Right arrow Articles by deBlois, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril

Shant Der Sarkissiana, Eve-Lyne Marchanda, David Duguaya, Pavel Hametb and Denis deBloisa,*

aDepartment of Pharmacology, University of Montreal, University of Montreal Hospital (CHUM) Research Center, 3840 St.-Urbain Street, Room 7-132B, Montreal, Quebec H2W 1T8, Canada
bDepartment of Medicine, University of Montreal, University of Montreal Hospital (CHUM) Research Center, 3850 St.-Urbain Street, Montreal, Quebec H2W 1T7, Canada

denis.deblois{at}umontreal.ca

* Corresponding author. Tel.: +1-514-890-8000x12919; fax: +1-514-412-7152.

Objective: Renin–angiotensin system inhibitors transiently induce apoptosis at the onset of cardiac hypertrophy regression in spontaneously hypertensive rats (SHRs). The focus of this study is to evaluate the cell selectivity of this response. Methods: SHRs were treated with valsartan or enalapril (30 mg kg–1 day–1) or placebo for 1 to 4 weeks. Stereological and morphological data were obtained from immunohistological analyses. Apoptosis was quantified by DEVDase (caspase-3-like) activity assay and immunoblot analysis of apoptosis-regulatory proteins (Bax and Bcl-2). Identification of the apoptotic cell type was conducted using in situ TUNEL labeling, in conjunction with {alpha}-sarcomeric actin or lectin immunoreactivity as markers for cardiomyocytes and endothelial cells, respectively. Results: Stereological analysis of the left ventricle revealed significant non-cardiomyocyte hyperplasia in placebo-treated SHRs (239±29x106 nuclei) as compared to untreated age-matched normotensive Wistar–Kyoto (WKY) rats (107±12x106). In contrast, the number of cardiomyocyte nuclei was comparable between untreated SHRs (48±4x106) and WKY rats. After 4 weeks of valsartan or enalapril treatment, SHRs showed significant reductions in systolic blood pressure (>28%), left ventricular hypertrophy (>9%) and cardiomyocyte cross-sectional area (>17%). Moreover, these treatments abolished non-cardiomyocyte hyperplasia in SHR left ventricle without affecting cardiomyocyte number, capillary density or number of capillary per cardiomyocyte nucleus. As a mechanism of cell deletion consistent with apoptosis induction, ventricles showed increased caspase-3 activation (>4.5-fold) as well as Bax to Bcl-2 protein ratio (>3.2-fold) within 2 weeks of valsartan or enalapril treatment. Immunohistological analysis revealed a significant increase in TUNEL-positive, lectin-negative non-cardiomyocytes, suggesting a rise in apoptotic interstitial fibroblasts in the left ventricle within 2 weeks of treatment with valsartan or enalapril (>63%), with a return to baseline (0.033±0.003%) at 4 weeks. Treatments did not affect right ventricular mass, apoptosis or cellularity. Conclusion: Cardiac apoptosis induction during regression of left ventricular hypertrophy reverses interstitial fibroblast hyperplasia in SHRs treated with inhibitors of the renin–angiotensin system.

KEYWORDS ACE inhibitors; Antihypertensive/diuretic agents; Apoptosis; Hypertension; Hypertrophy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.